Jose M. Rubio, MD, PhD

JCP
Clozapine Monitoring in the Post-REMS World: Some Guidance for Clinicians
ASCP Corner

May 5, 2025

While the abolition of REMS for clozapine expands access, the change could create confusion. Among the most relevant examples are mismatches between FDA recommendations for lifetime monitoring and the...
,
JCP
LAI Implementation After Schizophrenia Diagnosis
Original Research

April 19, 2023

Although long-acting injectable antipsychotic agents (LAIs) are effective in preventing relapse, their use in first-episode schizophrenia was low, and LAIs were rarely the first therapy for early-phase schizophrenia.
, , , et al
JCP
Predictors for Initiation of LAIs in Individuals With Early-Phase Schizophrenia
Original Research

February 13, 2023

Initiation of LAIs was predicted by greater switching of oral antipsychotics and more ED visits. LAIs are often used to respond to relapse rather than prevent it.
, , , et al
JCP
ASCP Corner

November 30, 2021

This ASCP Corner article discusses how to identify treatment-resistant patients who would benefit from clozapine and then offers tips on how to start the treatment conversation with these patients.
,
JCP
Review Article

November 24, 2020

Is the advantage of longer-term medication release with long-acting injectable antipsychotics offset by an increased risk of more prolonged and severe neuroleptic malignant syndrome? This systematic review and pooled...
, , , et al
JCP
ASCP Corner

April 26, 2017

This month's ASCP Corner discusses the significant problem of untreated psychiatric disorders and substance use disorders. The authors review the association between untreated illness and morbidity/mortality, look at ways...
,
JCP
ASCP Corner

March 29, 2017

This month's ASCP Corner discusses the significant problem of untreated psychosis. The authors review the factors that contribute to a longer time to treatment, the impact of untreated psychosis,...
,
JCP
Original Research

May 15, 2013

, , , et al